Akeso (FRA:4RY) Change In Receivables: €-60.3 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4RY Akeso Inc FRA:4RY
52 GF Score
Price €10.39
GF Value €16.35
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Akeso Change In Receivables?

Akeso FRA:4RY -1.69% 52 Change In Receivables is €-60.3 Mil as of Dec. 2025. GuruFocus rates FRA:4RY with a GF Score™ of 52/100 and a GF Value™ of €16.35 (Possible Value Trap). The stock has 5 warning signs investors should review.

Akeso's change in receivables for the quarter that ended in Dec. 2025 was €-25.9 Mil. It means Akeso's Accounts Receivable increased by €25.9 Mil from Jun. 2025 to Dec. 2025 .

Akeso's change in receivables for the fiscal year that ended in Dec. 2025 was €-60.5 Mil. It means Akeso's Accounts Receivable increased by €60.5 Mil from Dec. 2024 to Dec. 2025 .

Akeso's Accounts Receivable for the quarter that ended in Dec. 2025 was €123.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Akeso's Days Sales Outstanding for the six months ended in Dec. 2025 was 113.36.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Akeso's liquidation value for the six months ended in Dec. 2025 was €400.8 Mil.

Akeso  (FRA:4RY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Akeso's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=123.879/199.427*91
=113.36

2. In Ben Graham's calculation of liquidation value, Akeso's accounts receivable are only considered to be worth 75% of book value:

Akeso's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1106.795-855.368+0.75 * 123.879+0.5 * 112.96
=400.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akeso Change In Receivables Related Terms

Akeso Change In Receivables Historical Data

* Premium members only.

The historical data trend for Akeso's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akeso Change In Receivables Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial -14.16 -22.97 -3.26 -30.42 -60.47

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.09 -21.63 -8.27 -34.40 -25.92
FRA:4RY
52GF Score
Akeso Inc FRA:4RY
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akeso Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-60.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €-60.3 Mil mean?
Akeso (FRA:4RY) has a Change In Receivables of €-60.3 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Akeso and its competitors.
Is Akeso's Change In Receivables too high?
Akeso's current Change In Receivables is €-60.3 Mil. Overall, Akeso has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Akeso's Change In Receivables compare to VRTX and REGN?
Akeso's Change In Receivables of €-60.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Akeso and its competitors. Akeso's current Change In Receivables is €-60.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akeso stock overvalued right now?
Based on GuruFocus' analysis, Akeso (FRA:4RY) is currently considered Possible Value Trap. The stock's GF Value™ is €16.35, compared to a current price of €10.39 — trading 36.5% below its estimated fair value. The current Change In Receivables is €-60.3 Mil. Akeso's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Akeso (FRA:4RY), the current Change In Receivables is €-60.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akeso (FRA:4RY) Overvalued in 2026?

Based on GuruFocus' analysis, Akeso stock appears to be undervalued. The current stock price of €10.39 is trading 36.5% below its estimated GF Value™ of €16.35. GuruFocus considers Akeso to be Possible Value Trap.

Key valuation signals for FRA:4RY:

  • Change In Receivables: €-60.3 Mil
  • GF Value™: €16.35 vs. price of €10.39 (36.5% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the FRA:4RY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akeso Business Description

Address No. 6, Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
52GF Score

Get the complete analysis for FRA:4RY

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.39
Price
€16.35
GF Value